Interim analysis of an open-label extension study of sustained release fampridine in patients with multiple sclerosis

被引：0
|
作者：
Goodman, A. D.
Brown, T.
Krupp, L.
Schapiro, R.
Marinucci, L.
Cohen, R.
Blight, A.
机构：
来源：
MULTIPLE SCLEROSIS | 2009年 / 15卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：S13 / S13
页数：1
相关论文
共 50 条
  • [41] Gastrointestinal tolerability of delayed-release dimethyl fumarate in a multicenter, open-label study of patients with relapsing multiple sclerosis
    Fox, E. J.
    Vasquez, A.
    Grainger, W.
    Ma, T. S.
    von Hehn, C.
    Walsh, J.
    Li, J.
    Zambrano, J.
    MULTIPLE SCLEROSIS JOURNAL, 2014, 20 : 205 - 205
  • [42] INTERIM ANALYSIS OF NINTEDANIB IN AN OPEN-LABEL EXTENSION OF THE INPULSIS (R) TRIALS (INPULSIS (R)-ON)
    Crestani, B.
    Ogura, T.
    Pelling, K.
    Coeck, C.
    Quaresma, M.
    Kreuter, M.
    Kaye, M.
    THORAX, 2015, 70 : A77 - A78
  • [43] Sustained-release fampridine and the role of ion channel dysfunction in multiple sclerosis
    Krishnan, Arun V.
    Kiernan, Matthew C.
    MULTIPLE SCLEROSIS JOURNAL, 2013, 19 (04) : 385 - 391
  • [44] Interim Results of an Open-Label Study to Assess the Effects of Delayed-release Dimethyl Fumarate on Lymphocyte Subsets and Immunoglobulins in Patients with Relapsing-remitting Multiple Sclerosis
    Von Hehn, Christian
    Mehta, Devangi
    Prada, Claudia
    Yang, Lili
    Liu, Shifang
    Ray, Soma
    Sheikh, Sarah
    NEUROLOGY, 2017, 88
  • [45] Duloxetine Is Effective in Treating Depression in Multiple Sclerosis Patients: An Open-Label Multicenter Study
    Solaro, Claudio
    Bergamaschi, Roberto
    Rezzani, Cristiana
    Mueller, Margit
    Trabucco, Erika
    Bargiggia, Valeria
    Dematteis, Francesca
    Mattioda, Alessandra
    Cimino, Vincenzo
    Restivo, Domenico
    Patti, Francesco
    Cavalla, Paola
    CLINICAL NEUROPHARMACOLOGY, 2013, 36 (04) : 114 - 116
  • [46] Evobrutinib Efficacy is Maintained Over Two Years in an Open-label Phase II Study Extension in Patients with Relapsing Multiple Sclerosis
    Montalban, Xavier
    Arnold, Douglas L.
    Weber, Martin S.
    Staikov, Ivan
    Piasecka-Stryczynska, Karolina
    Martin, Emily C.
    Mandel, Matthew
    Dangond, Fernando
    Wolinsky, Jerry S.
    NEUROLOGY, 2021, 96 (15)
  • [47] Five years of ocrelizumab in relapsing multiple sclerosis OPERA studies open-label extension
    Hauser, Stephen L.
    Kappos, Ludwig
    Arnold, Douglas L.
    Bar-Or, Amit
    Brochet, Bruno
    Naismith, Robert T.
    Traboulsee, Anthony
    Wolinsky, Jerry S.
    Belachew, Shibeshih
    Koendgen, Harold
    Levesque, Victoria
    Manfrini, Marianna
    Model, Fabian
    Hubeaux, Stanislas
    Mehta, Lahar
    Montalban, Xavier
    NEUROLOGY, 2020, 95 (13) : E1854 - E1867
  • [48] Safety of Evobrutinib in Patients With Relapsing Multiple Sclerosis is Maintained in a Long-term Open-label Extension of a Phase II Study
    Montalban, Xavier
    Arnold, Douglas L.
    Weber, Martin S.
    Staikov, Ivan
    Piasecka-Stryczynska, Karolina
    Martin, Emily C.
    Mandel, Matthew
    Zima, Yulia
    Shaw, Jamie
    Dangond, Fernando
    Grenningloh, Roland
    Li, Ying
    Tomic, Davorka
    Wolinsky, Jerry S.
    NEUROLOGY, 2021, 96 (15)
  • [49] Safety And Tolerability Of Nintedanib In Patients With Ipf: Interim Analysis From An Open-Label Extension Of The Inpulsis® Trials (inpulsis®-On)
    Crestani, B.
    Ogura, T.
    Pelling, K.
    Quaresma, M.
    Coeck, C.
    Kaye, M.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2015, 191
  • [50] Bupropion sustained-release for the treatment of dysthymic disorder: An open-label study
    Hellerstein, DJ
    Batchelder, S
    Kreditor, D
    Fedak, M
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2001, 21 (03) : 325 - 329
12345